The Board of Eliem Therapeutics, Inc. has approved a corporate reorganization plan to conserve financial resources. As part of the reorganization, the Company will reduce its workforce by approximately 55% in the first half of 2023. In connection with this reorganization, Erin Lavelle, chief financial officer will depart the Company following a short transition period.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.29 USD | -4.27% | +0.73% | +207.04% |
May. 15 | Eliem Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 11 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
1st Jan change | Capi. | |
---|---|---|
+207.04% | 258M | |
+18.34% | 125B | |
+15.06% | 108B | |
-6.39% | 23.64B | |
+2.39% | 22.39B | |
-12.11% | 17.78B | |
-41.64% | 16.43B | |
-12.07% | 16.34B | |
+1.05% | 13.56B | |
+25.87% | 11.59B |
- Stock Market
- Equities
- ELYM Stock
- News Eliem Therapeutics, Inc.
- Erin Lavelle to Depart as Chief Financial Officer of Eliem Therapeutics, Inc